uniQure N.V.
QURE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.52B
Close$
$-8.52
139.3% downside
Current Fair Value
139.3% downsideOvervalued by 139.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.52 Billion |
|---|---|
| Enterprise Value | $1.17 Billion |
| Earnings per Share | $-3.46 |
| Beta | 0.94 |
| Outstanding Shares | 69,900,863 |
Return
| Return on Equity | -77.83% |
|---|---|
| Return on Assets | -25.60% |
| Return on Invested Capital | -29.63% |
Valuation & Multiples
| P/E Ratio | -6.13 |
|---|---|
| PEG | -5.33 |
| Price to Sales | - |
| Price to Book Ratio | 5.43 |
| Enterprise Value to Revenue | 62.57 |
| Enterprise Value to EBIT | -4.37 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-0.92
Consensus analyst estimateRevenue Estimate
$6.17 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 1, 2027
EPS Estimate
$-0.89
Consensus analyst estimateRevenue Estimate
$6.66 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 21.60% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.96%▼ 95.37% |
|---|---|
| Total Invested | $63.43M▼ 97.91% |
| Investors Holding | 42▼ 260.00% |
About uniQure N.V.
221 employees
CEO: Matthew C. Kapusta
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...